Teneligliptin: expectations for its pleiotropic action

Bibliography

• Del Prato S. In search of normoglycaemia in diabetes: controlling postprandial glucose. Int J Obes Relat Metab Disord 2002;26:S9-S17
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Guideline for management of post meal glucose in diabetes. International diabetes federation. 2011. Available from: http://www.idf.org/2011-guideline-management-postmeal-glucose-diabetes
   Google Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33(7):1389-94
   PubMedGoogle Scholar
• Risso A, Mercuri F, Quagliaro L, et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281(5):E924-30
   PubMed Web of Science ®Google Scholar
• Piconi L, Quagliaro L, Da Ros R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly (ADP-ribose) polymerase. J Thromb Haemost 2004;2(8):1453-9
   PubMed Web of Science ®Google Scholar
• Mita T, Otsuka A, Azuma K, et al. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2007;358(3):679-85
   PubMed Web of Science ®Google Scholar
• Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57(5):1349-54
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295(14):1681-7
   PubMed Web of Science ®Google Scholar
• Su G, Mi SH, Tao H, et al. Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care 2013;36(4):1026-32
   PubMed Web of Science ®Google Scholar
• Balakumar P, Dhanaraj SA. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Cell Signal 2013;25(9):1799-803
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33(2):187-215
   PubMed Web of Science ®Google Scholar
• Aroor AR, Sowers JR, Jia G, et al. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol 2014;307(4):H477-92
   PubMed Web of Science ®Google Scholar
• van Genugten RE, Möller-Goede DL, van Raalte DH, et al. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes Obes Metab 2013;15(7):593-606
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369(14):1327-35
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369(14):1317-26
   PubMed Web of Science ®Google Scholar
• Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today (Barc) 2013;49(10):615-29
   PubMed Web of Science ®Google Scholar
• Fukuda-Tsuru S, Anabuki J, Abe Y, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 2012;696(1–3):194-202
   PubMed Web of Science ®Google Scholar
• Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013;434(2):191-6
   PubMed Web of Science ®Google Scholar
• Fukuda-Tsuru S, Kakimoto T, Utsumi H, et al. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol 2014;723:207-15
   PubMed Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85(1):9-24
   PubMed Web of Science ®Google Scholar
• Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340(2):248-55
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency. Tenelia application document. 2012. Available from: http://www.pmda.go.jp/english/service/pdf/drugs/tenelia_jun2012_e.pdf
   Google Scholar
• Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinical profile of teneligliptin(3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem 2012;20(19):5705-19
   PubMed Web of Science ®Google Scholar
• Nakamaru Y, Hayashi Y, Ikegawa R, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica 2014;44(3):242-53
   PubMed Web of Science ®Google Scholar
• Halabi A, Maatouk H, Siegler KE, et al. Pharmacokinetics of teneligliptin in subjects with renal impairment. Clin Pharm Drug Dev 2013;2:246-54
   PubMed Web of Science ®Google Scholar
• Halabi A, Maatouk H, Siegler KE, et al. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Clin Pharm Drug Dev 2014;3(4):290-6
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15(9):810-18
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 2014;16(5):418-25
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2013;4(6):576-84
   PubMed Web of Science ®Google Scholar
• Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012;14(11):1040-6
   PubMed Web of Science ®Google Scholar
• Tanaka S, Suzuki I, Aoki C, et al. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther 2014;16(12):840-5
   PubMed Web of Science ®Google Scholar
• Tsuchimochi W, Ueno H, Yamashita E, et al. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients. Endocr J 2014; 10.1507/endocrj.EJ14-0393
   PubMed Web of Science ®Google Scholar
• Otsuki H, Kosaka T, Nakamura K, et al. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol 2014;46(2):427-32
   PubMed Web of Science ®Google Scholar
• Nakagami H, Pang Z, Shimosato T, et al. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens Res 2014;37:629-35
   PubMed Web of Science ®Google Scholar
• Takase B, Nagata M. Subacute effect of a novel dipeptidyl peptidase-4 inhibitor teneligliptin on endothelial function in humans. J N Remedies Clin 2013;50:698-704
   Google Scholar
• Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000;16(2):125-32
   PubMed Web of Science ®Google Scholar
• Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother 2013;14(15):2047-58
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins for 2014. Expert Opin Pharmacother 2014;10:1-20
   Google Scholar
• Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011;13(3):294-307
   PubMed Web of Science ®Google Scholar